Name: UROGEN PHARMA LTD (URGN) Stock
Brand: UROGEN PHARMA LTD
Rating: 6 (3 reviews)

URGN Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: UroGen Pharma Ltd.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 days ago - By: UroGen Pharma Ltd.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 days ago - By: UroGen Pharma Ltd.

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

13 days ago - By: UroGen Pharma Ltd.

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

a month ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

4 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

a month ago - By: The Motley Fool

UroGen (URGN) Q3 2025 Earnings Call Transcript

a month ago - By: UroGen Pharma Ltd.

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

a month ago - By: UroGen Pharma Ltd.

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

a month ago - By: UroGen Pharma Ltd.

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

a month ago - By: UroGen Pharma Ltd.

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

a month ago - By: UroGen Pharma Ltd.

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

a month ago - By: UroGen Pharma Ltd.

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

a month ago - By: Zacks Investment Research - Mentions: FENC

Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

a month ago - By: UroGen Pharma Ltd.

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

a month ago - By: UroGen Pharma Ltd.

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

a month ago - By: Zacks Investment Research - Mentions: CRSP

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?

a month ago - By: UroGen Pharma Ltd.

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

2 months ago - By: UroGen Pharma Ltd.

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

2 months ago - By: UroGen Pharma Ltd.

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

3 months ago - By: UroGen Pharma Ltd.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: UroGen Pharma Ltd.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: UroGen Pharma Ltd.

UroGen Pharma to Present at Upcoming Investor Conferences

4 months ago - By: UroGen Pharma Ltd.

UroGen Pharma to Present at Upcoming Investor Conferences

4 months ago - By: The Motley Fool

UroGen (URGN) Q2 Revenue Rises 11%

4 months ago - By: Zacks Investment Research - Mentions: TCRX

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: UroGen Pharma Ltd.

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

4 months ago - By: UroGen Pharma Ltd.

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

4 months ago - By: UroGen Pharma Ltd.

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

4 months ago - By: UroGen Pharma Ltd.

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

4 months ago - By: UroGen Pharma Ltd.

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

4 months ago - By: Bragar Eagel & Squire

UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit

4 months ago - By: UroGen Pharma Ltd.

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

4 months ago - By: UroGen Pharma Ltd.

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

5 months ago - By: Bragar Eagel & Squire

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit

UROGEN PHARMA LTD (URGN) Stock News

URGN Latest News, Press Relases and Analysis